دورية أكاديمية
Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
| العنوان: | Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. |
|---|---|
| المؤلفون: | Breen KE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Symecko H; Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania., Spielman K; Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania., Gebert R; Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York., Shah IH; Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York., Pundock S; Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania., Batson M; Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania., Narayan VK; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Stadler ZK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Autio KA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Abida W; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Danila DC; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Scher HI; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Morris MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Hamilton JG; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York., Robson ME; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Domchek SM; Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania., Carlo MI; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. |
| المصدر: | The Journal of urology [J Urol] 2023 May; Vol. 209 (5), pp. 918-927. Date of Electronic Publication: 2023 Mar 28. |
| نوع المنشور: | Multicenter Study; Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 0376374 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3792 (Electronic) Linking ISSN: 00225347 NLM ISO Abbreviation: J Urol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2019- : [Philadelphia, PA] : Wolters Kluwer Original Publication: Baltimore : Lippincott Williams & Wilkins |
| مواضيع طبية MeSH: | Genetic Testing* , Prostatic Neoplasms*/diagnosis , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/therapy, Male ; Humans ; Prospective Studies ; Genetic Counseling ; Counseling |
| مستخلص: | Purpose: Genetic testing may alter clinical management for individuals with metastatic prostate cancer by identifying additional therapies. Traditional counseling models are unlikely to enable time-sensitive therapeutic decision-making. This study aimed to determine the feasibility and clinical impact of an alternative hereditary genetic testing model. Materials and Methods: As part of a multicenter, single-arm prospective trial, individuals with advanced prostate cancer were referred by their oncologist for testing of 14 genes associated with hereditary prostate cancer. Pretest education (brochure and video) was provided in the oncology clinic. Questionnaires assessing participant satisfaction with both pretest education and decision to undergo genetic testing were collected. A genetic counselor contacted participants by phone to obtain family history and discuss results. Medical records were queried to determine whether a change in clinical management was discussed. Results: Of 501 participants consented to germline analysis, 51 (10.2%) had at least 1 pathogenic/likely pathogenic variant. Change in treatment was discussed with 22/48 (45.8%) of eligible participants who tested positive. Feasibility of this model was assessed by participant satisfaction and turnaround time. Average±SD satisfaction with the pretest education (15.5±2.2, 4-20 scale) and with the decision to undergo genetic testing (17.1±2.9, 4-20 scale) were both high. Results were returned 20 days (median) after sample collection. Conclusions: Oncologist-initiated germline genetic testing in collaboration with a genetic counselor is a feasible approach to testing advanced prostate cancer patients with impactful clinical actionability. The testing model and educational material serve as resources to clinicians treating prostate cancer patients. |
| التعليقات: | Comment in: J Urol. 2023 May;209(5):926-927. (PMID: 36974723) |
| References: | J Genet Couns. 2020 Dec;29(6):1126-1141. (PMID: 32314856) N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255) Eur Urol Focus. 2018 Jan;4(1):121-127. (PMID: 29162421) Eur Urol. 2020 Dec;78(6):786-811. (PMID: 32616405) JCO Precis Oncol. 2018;2018:. (PMID: 30761386) Cancer. 2017 Sep 15;123(18):3532-3539. (PMID: 28608931) N Engl J Med. 2016 Aug 4;375(5):443-53. (PMID: 27433846) J Genet Couns. 2021 Aug;30(4):924-937. (PMID: 33817891) J Genet Couns. 2018 Feb;27(1):16-20. (PMID: 29052810) Med Decis Making. 1996 Jan-Mar;16(1):58-64. (PMID: 8717600) JAMA Oncol. 2019 Apr 01;5(4):523-528. (PMID: 30730552) Genet Med. 2017 Oct;19(10):1105-1117. (PMID: 28492532) Nat Rev Clin Oncol. 2019 Jun;16(6):386-396. (PMID: 30783251) PLoS One. 2015 Oct 13;10(10):e0139440. (PMID: 26460686) J Urol. 2022 Nov;208(5):1007-1017. (PMID: 35930793) J Genet Couns. 2012 Oct;21(5):645-51. (PMID: 22566244) J Clin Oncol. 2020 Aug 20;38(24):2798-2811. (PMID: 32516092) Cancer Med. 2021 Jul;10(13):4532-4541. (PMID: 34102012) Clin Cancer Res. 2020 Jun 1;26(11):2487-2496. (PMID: 32086346) Prostate. 2021 Aug;81(11):754-764. (PMID: 34057231) J Clin Oncol. 2019 Jun 10;37(17):1455-1459. (PMID: 30978156) JCO Oncol Pract. 2021 Feb;17(2):e204-e216. (PMID: 32970524) Clin Genitourin Cancer. 2019 Aug;17(4):275-282.e1. (PMID: 31171481) Genet Med. 2021 Nov;23(11):2105-2113. (PMID: 34257420) JCO Precis Oncol. 2021 Sep 01;5:. (PMID: 34589662) N Engl J Med. 2020 May 28;382(22):2091-2102. (PMID: 32343890) J Genet Couns. 2019 Jun;28(3):673-691. (PMID: 30825358) Genet Med. 2021 Aug;23(8):1438-1449. (PMID: 33824502) J Clin Oncol. 2020 Nov 10;38(32):3763-3772. (PMID: 32795228) J Genet Couns. 2021 Oct;30(5):1361-1378. (PMID: 34355839) |
| معلومات مُعتمدة: | P30 CA008748 United States CA NCI NIH HHS; P30 CA016520 United States CA NCI NIH HHS; P50 CA092629 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: delivery of health care; genetic counseling; genetic testing; patient education as topic; prostatic neoplasms |
| تواريخ الأحداث: | Date Created: 20230328 Date Completed: 20230410 Latest Revision: 20240502 |
| رمز التحديث: | 20240502 |
| مُعرف محوري في PubMed: | PMC10081955 |
| DOI: | 10.1097/JU.0000000000003186 |
| PMID: | 36974724 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1527-3792 |
|---|---|
| DOI: | 10.1097/JU.0000000000003186 |